WO1999036440A3 - Expression of fusion proteins - Google Patents

Expression of fusion proteins Download PDF

Info

Publication number
WO1999036440A3
WO1999036440A3 PCT/GB1999/000152 GB9900152W WO9936440A3 WO 1999036440 A3 WO1999036440 A3 WO 1999036440A3 GB 9900152 W GB9900152 W GB 9900152W WO 9936440 A3 WO9936440 A3 WO 9936440A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
expression
fusion proteins
organism
virus
Prior art date
Application number
PCT/GB1999/000152
Other languages
French (fr)
Other versions
WO1999036440A2 (en
Inventor
Robert Edward Hawkins
Hayley Ann Whittington
Original Assignee
Univ Bristol
Robert Edward Hawkins
Hayley Ann Whittington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bristol, Robert Edward Hawkins, Hayley Ann Whittington filed Critical Univ Bristol
Priority to AU21737/99A priority Critical patent/AU2173799A/en
Priority to EP99901731A priority patent/EP1066327A2/en
Publication of WO1999036440A2 publication Critical patent/WO1999036440A2/en
Publication of WO1999036440A3 publication Critical patent/WO1999036440A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

This invention provides a method of producing a fusion protein comprising an antibody portion and a further biologically active portion, the method comprising forming a virus-based construct including a DNA sequence encoding the fusion protein and infecting cells or an organism with the thus constructed virus-based construct whereby the fusion protein is expressed in in vitro in the cells, or in vivo in the organism.
PCT/GB1999/000152 1998-01-16 1999-01-18 Expression of fusion proteins WO1999036440A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU21737/99A AU2173799A (en) 1998-01-16 1999-01-18 Expression of fusion proteins
EP99901731A EP1066327A2 (en) 1998-01-16 1999-01-18 Expression of fusion proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9800927.7 1998-01-16
GBGB9800927.7A GB9800927D0 (en) 1998-01-16 1998-01-16 Recombinant adenoviral delivery of antibody fusion proteins

Publications (2)

Publication Number Publication Date
WO1999036440A2 WO1999036440A2 (en) 1999-07-22
WO1999036440A3 true WO1999036440A3 (en) 1999-09-16

Family

ID=10825407

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000152 WO1999036440A2 (en) 1998-01-16 1999-01-18 Expression of fusion proteins

Country Status (4)

Country Link
EP (1) EP1066327A2 (en)
AU (1) AU2173799A (en)
GB (1) GB9800927D0 (en)
WO (1) WO1999036440A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004031341D1 (en) 2003-07-21 2011-03-24 Transgene Sa MULTIFUNCTIONAL CYTOKINE
EP1925626A1 (en) * 2003-07-21 2008-05-28 Transgene S.A. Novel multifunctional cytokines

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CHESTER K A ET AL: "Clinical issues in antibody design.", TRENDS IN BIOTECHNOLOGY, (1995 AUG) 13 (8) 294-300. REF: 54 JOURNAL CODE: ALJ. ISSN: 0167-7799., ENGLAND: United Kingdom, XP002106262 *
CHESTER K A ET AL: "Phage libraries for generation of clinically useful antibodies.", LANCET, (1994 FEB 19) 343 (8895) 455-6. JOURNAL CODE: L0S. ISSN: 0140-6736., ENGLAND: United Kingdom, XP002106266 *
CHESTER, KERRY A. ET AL: "Opportunities with phage technology and antibody engineering of fusion proteins", ADV. DRUG DELIVERY REV. (1996), 22(3), 303-313 CODEN: ADDREP;ISSN: 0169-409X, XP002106264 *
CONNELLY R J ET AL: "Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes.", INTERNATIONAL IMMUNOLOGY, (1998 DEC) 10 (12) 1863-72. JOURNAL CODE: AY5. ISSN: 0953-8178., ENGLAND: United Kingdom, XP002106267 *
GILLILAND L K ET AL: "Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments.", TISSUE ANTIGENS, (1996 JAN) 47 (1) 1-20. JOURNAL CODE: VSV. ISSN: 0001-2815., Denmark, XP002035286 *
HAWKINS R E ET AL: "Antibodies: from genes to targeted cancer gene therapy [editorial].", GENE THERAPY, (1998 DEC) 5 (12) 1581-3. JOURNAL CODE: CCE. ISSN: 0969-7128., ENGLAND: United Kingdom, XP002106269 *
HORNICK J L ET AL: "Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin - 2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties.", BLOOD, (1997 JUN 15) 89 (12) 4437-47. JOURNAL CODE: A8G. ISSN: 0006-4971., United States, XP002106263 *
KOZARSKY K F ET AL: "Gene therapy: adenovirus vectors.", CURRENT OPINION IN GENETICS AND DEVELOPMENT, (1993 JUN) 3 (3) 499-503. REF: 31 JOURNAL CODE: BJC. ISSN: 0959-437X., ENGLAND: United Kingdom, XP002107739 *
SAVAGE ET AL: "A recombinant single chain antibody interleukin-2 fusion protein", BR. J. CANCER, vol. 67, 1993, pages 304 - 310, XP002106265 *
VERMA I M ET AL: "Gene therapy -- promises, problems and prospects [news].", NATURE, (1997 SEP 18) 389 (6648) 239-42. JOURNAL CODE: NSC. ISSN: 0028-0836., ENGLAND: United Kingdom, XP002910793 *
WATKINS, S. J. ET AL: "The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery", GENE THER. (1997), 4(10), 1004-1012 CODEN: GETHEC;ISSN: 0969-7128, XP002106261 *
WHITTINGTON H A ET AL: "Recombinant adenoviral delivery for in vivo expression of scFv antibody fusion proteins.", GENE THERAPY, (1998 JUN) 5 (6) 770-7. JOURNAL CODE: CCE. ISSN: 0969-7128., ENGLAND: United Kingdom, XP002106268 *

Also Published As

Publication number Publication date
GB9800927D0 (en) 1998-03-11
EP1066327A2 (en) 2001-01-10
WO1999036440A2 (en) 1999-07-22
AU2173799A (en) 1999-08-02

Similar Documents

Publication Publication Date Title
ZA200110161B (en) Anti-avB3 recombinant human antibodies, nucleic acids encoding same and methods of use.
WO2001018172A3 (en) Fibroblast growth factor-like polypeptides
WO2000006737A3 (en) Streptococcus pneumoniae proteins and nucleic acid molecules
WO2002014358A3 (en) Novel secreted proteins and their uses
AU2001241407A1 (en) Nucleic acids, proteins, and antibodies
WO2000006736A3 (en) Nucleic acids and proteins from group b streptococcus
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
WO2001064738A3 (en) Heparin-binding amino acid sequences derived from human proteins facilitating penetration of a substance of interest into cells and/or cell nuclei
WO2001032882A3 (en) Nucleic acids and proteins from group b streptococcus
EP0744408A3 (en) Rhesus ob protein and DNA
CA2445785A1 (en) Artificial kidney having function of metabolizing protein and method of constructing the same
AU2002344219A1 (en) Fusion proteins of biologically active peptides and antibodies
WO1999036440A3 (en) Expression of fusion proteins
WO2002008417A1 (en) Process for producing recombinant protein
EP1220896A4 (en) Novel human lipase proteins, nucleic acids encoding them, and uses of both of these
WO2004089973A3 (en) Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
WO2002016578A3 (en) Secreted proteins and methods of using same
WO2000053759A8 (en) Expression of human alpha-fetoprotein in mammalian cells
EP1790730A3 (en) Streptococcus pneumoniae proteins and nucleic acid molecules
WO2001027290A3 (en) Aortic carboxypeptidase-like protein and nucleic acids encoding same
AU2002250346A1 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
AU2001229508A1 (en) Nucleic acids, proteins, and antibodies
AU2002217521A1 (en) Method of identifying dna encoding physiologically active polypeptide in mammalian body
WO2001025430A3 (en) Novel human membrane proteins
AU2002257016A1 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09617123

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999901731

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999901731

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999901731

Country of ref document: EP